Patients with PIRA, particularly early PIRA, had increased risk for disability and use of a cane at follow-up.
Progression independent of relapse activity (PIRA) is increasingly recognized as an indicator of disease progression in patients with relapsing multiple sclerosis (NEJM JW Neurol 2022 Mar 1 and Brain 2022; 145:3147). In this retrospective, single-center analysis, 1128 patents with a first demyelinating event were followed for up to 7 years to assess the effects of PIRA on disability progression.
PIRA was observed in 25% of patients, of whom 31% had PIRA within 5 years of diagnosis with multiple sclerosis. Of 277 patients with PIRA and MRI scans, 51% developed PIRA associated with new MRI activity. Patients with PIRA were older, had more T2 brain lesions, and more often had oligoclonal bands in CSF. Patients with PIRA had a 0.18-point annual …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)